TrialMenopause (New York, N.Y.)2026

Efficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial.

Yaping Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.